Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
13.23
Dollar change
+0.50
Percentage change
3.93
%
IndexRUT P/E- EPS (ttm)-0.75 Insider Own15.07% Shs Outstand35.17M Perf Week25.05%
Market Cap467.81M Forward P/E18.50 EPS next Y0.71 Insider Trans2.74% Shs Float30.04M Perf Month20.93%
Income-24.41M PEG- EPS next Q-0.19 Inst Own64.51% Short Float18.30% Perf Quarter20.82%
Sales130.19M P/S3.59 EPS this Y58.22% Inst Trans-4.54% Short Ratio12.41 Perf Half Y-7.93%
Book/sh2.00 P/B6.61 EPS next Y328.19% ROA-10.41% Short Interest5.50M Perf Year-37.68%
Cash/sh2.34 P/C5.65 EPS next 5Y15.00% ROE-49.84% 52W Range7.60 - 28.25 Perf YTD18.12%
Dividend Est.- P/FCF196.56 EPS past 5Y- ROI-9.39% 52W High-53.17% Beta0.48
Dividend TTM- Quick Ratio2.60 Sales past 5Y27.34% Gross Margin69.55% 52W Low74.08% ATR (14)0.72
Dividend Ex-Date- Current Ratio2.82 EPS Y/Y TTM-44.20% Oper. Margin0.62% RSI (14)73.77 Volatility8.32% 6.28%
Employees315 Debt/Eq2.71 Sales Y/Y TTM46.95% Profit Margin-18.75% Recom1.00 Target Price26.20
Option/ShortYes / Yes LT Debt/Eq2.70 EPS Q/Q-822.91% Payout- Rel Volume1.89 Prev Close12.73
Sales Surprise-3.97% EPS Surprise-500.46% Sales Q/Q78.83% EarningsMar 19 AMC Avg Volume443.00K Price13.23
SMA2019.71% SMA5024.29% SMA200-3.70% Trades Volume837,654 Change3.93%
Date Action Analyst Rating Change Price Target Change
Sep-08-22Resumed B. Riley Securities Buy $17
Oct-14-21Resumed B. Riley Securities Buy $16
Sep-24-21Initiated Aegis Capital Buy $15
Jul-02-21Initiated Ladenburg Thalmann Buy $14.25
Mar-21-24 09:55AM
Mar-19-24 09:52PM
06:51PM
05:45PM
Mar-13-24 06:35AM
07:00AM Loading…
Mar-05-24 07:00AM
Mar-04-24 08:28PM
Feb-21-24 06:47AM
Feb-15-24 04:01PM
Jan-29-24 07:00AM
Jan-11-24 07:00AM
Jan-03-24 07:15AM
07:00AM
Dec-24-23 01:08PM
Nov-29-23 07:00AM
07:00AM Loading…
Nov-20-23 07:00AM
Nov-14-23 12:56PM
Nov-13-23 05:07PM
04:01PM
Oct-30-23 08:00AM
Oct-24-23 07:00AM
Sep-29-23 08:00AM
Sep-26-23 08:00AM
Sep-21-23 01:03PM
Aug-11-23 01:05PM
Aug-10-23 09:54AM
Aug-09-23 04:14PM
04:01PM
Jul-31-23 07:00AM
Jul-28-23 02:56PM
03:42PM Loading…
Jul-26-23 03:42PM
09:00AM
Jul-20-23 10:29AM
Jul-19-23 12:17PM
07:00AM
Jul-18-23 05:00PM
04:05PM
04:04PM
04:01PM
Jul-05-23 06:15PM
Jun-29-23 06:15PM
Jun-23-23 06:15PM
Jun-16-23 06:00PM
May-17-23 08:00AM
May-16-23 11:57AM
May-15-23 11:21AM
May-12-23 01:48PM
06:26AM
May-11-23 05:15PM
04:29PM
04:01PM
May-08-23 12:07PM
May-04-23 08:00AM
04:59AM
May-03-23 06:44AM
May-02-23 04:42PM
09:40AM
07:00AM
May-01-23 08:50AM
Apr-28-23 06:00PM
05:00AM
Apr-27-23 08:05AM
08:00AM
Apr-24-23 08:43AM
07:09AM
Apr-20-23 08:31AM
Apr-19-23 06:15PM
08:31AM
Apr-18-23 06:24AM
Apr-14-23 08:50AM
Apr-13-23 06:15PM
Apr-12-23 09:40AM
Apr-09-23 04:04PM
Apr-05-23 09:34AM
Apr-04-23 05:37AM
Apr-03-23 06:53AM
Mar-29-23 08:50AM
Mar-28-23 02:59PM
07:00AM
Mar-27-23 08:51AM
Mar-24-23 05:42AM
Mar-23-23 04:06PM
Mar-13-23 07:00AM
Mar-06-23 08:00AM
Mar-02-23 08:00AM
Feb-16-23 06:42AM
Feb-15-23 07:00AM
Feb-03-23 08:50AM
Feb-02-23 06:30AM
Jan-23-23 07:00AM
Jan-21-23 07:33AM
Jan-18-23 08:50AM
Jan-05-23 07:00AM
Dec-25-22 07:24AM
Dec-21-22 09:21AM
Dec-16-22 07:00AM
Dec-14-22 03:24PM
09:41AM
06:32AM
06:31AM
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Opaleye Management Inc.10% OwnerMar 28 '24Buy12.8250,000641,0003,745,600Mar 28 06:07 PM
BAUM MARK LCHIEF EXECUTIVE OFFICERMar 22 '24Buy11.599,000104,3102,137,525Mar 25 07:00 AM
Opaleye Management Inc.10% OwnerMar 20 '24Buy9.6550,600488,2903,695,600Mar 22 11:52 AM
SAHAREK JOHN P.CEO of ImprimisRxMar 01 '24Option Exercise8.755,00043,750254,803Mar 06 06:06 AM
BAUM MARK LCHIEF EXECUTIVE OFFICERFeb 20 '24Option Exercise10.67150,0001,600,5002,188,361Feb 21 07:29 PM
BOLL ANDREW R.CHIEF FINANCIAL OFFICERFeb 20 '24Option Exercise10.6745,000480,150586,569Feb 21 07:29 PM
SAHAREK JOHN P.CEO of ImprimisRxFeb 20 '24Option Exercise10.6730,000320,100262,419Feb 21 07:30 PM
BAUM MARK LCHIEF EXECUTIVE OFFICERFeb 07 '24Option Exercise7.7115,400118,7342,038,361Feb 08 07:30 AM
BOLL ANDREW R.CHIEF FINANCIAL OFFICERFeb 07 '24Option Exercise7.717,40057,054541,569Feb 08 07:30 AM
BAUM MARK LChief Executive OfficerNov 16 '23Buy8.117,50060,8252,022,961Nov 16 04:45 PM
Opaleye Management Inc.10% OwnerNov 15 '23Buy8.0325,000200,7353,645,000Nov 16 04:05 PM
Opaleye Management Inc.10% OwnerSep 20 '23Buy14.495,98386,7103,620,000Sep 20 06:39 PM
Opaleye Management Inc.10% OwnerSep 19 '23Buy14.6514,017205,3663,614,017Sep 20 06:39 PM
Makary Martin A.DirectorAug 14 '23Buy16.9220,000338,40045,000Aug 15 07:30 AM
BAUM MARK LChief Executive OfficerAug 14 '23Buy17.055,80098,8902,015,461Aug 15 07:30 AM
BAUM MARK LChief Executive OfficerApr 03 '23Option Exercise8.99180,0001,618,2001,664,962Apr 04 07:54 PM
BOLL ANDREW R.Chief Financial OfficerMar 31 '23Option Exercise6.0090,000540,000358,461Apr 04 07:50 PM